Quarterly Updates19 May 2026, 08:11 pm
Mankind Pharma: FY26 Revenue Up 17% YoY to ₹14,278 Cr
AI Summary
Mankind Pharma Ltd announced its Q4FY26 and FY26 financial results, reporting an 11.8% YoY increase in revenue for Q4FY26, reaching ₹3,443 crore, and a 17.0% YoY increase for FY26, totaling ₹14,278 crore. The adjusted EBITDA margin for Q4FY26 stood at 27.1%, with a PAT margin of 16.2%. Domestic revenue grew by 13.4% in Q4FY26. For FY26, domestic revenue reached ₹12,217 crore, up 14.4% YoY, while exports increased by 34.5% YoY to ₹2,061 crore.
Key Highlights
- Q4FY26 revenue increased by 11.8% YoY to ₹3,443 crore.
- FY26 revenue rose by 17.0% YoY to ₹14,278 crore.
- Q4FY26 adjusted EBITDA margin at 27.1%, up 400 bps YoY.
- Domestic revenue grew by 13.4% YoY in Q4FY26.
- FY26 diluted EPS at ₹46.3, down by 5.7% YoY.
Price Impact
More from MANKIND